FibroBiologics, Inc.

FBLG Nasdaq SEC CIK 1958777
Follow FibroBiologics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$4M +29.9% vs same quarter last year
EPS, diluted −$0.38 +85.8% vs same quarter last year
Operating cash flow −$2.8M +30.6% vs same quarter last year
Operating income −$4.1M +19.2% vs same quarter last year
Net income by quarter
−$3.1M
−$5M
−$4.7M
−$5.8M
−$3.2M
−$5M
−$4.1M
−$4M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income5 fiscal years
−$20M−$15M−$10M−$5M$0FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$18.6M
FY24−$11.2M
FY23−$16.5M
FY22−$5.1M
FY21-
Free cash flowOperating cash flow minus capital expenditure
−$20M−$15M−$10M−$5M$0FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$16.7M
FY24−$12.1M
FY23−$6.9M
FY22-
FY21-